The FDA approved brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy for the treatment of adult patients with previously untreated stage III or IV classic Hodgkin lymphoma (cHL).
According to Joseph M. Connors, MD, the clinical director of the Centre for Lymphoid Cancer at BC Cancer, in Vancouver, British Columbia, “The standard of care for treating newly diagnosed advanced Hodgkin lymphoma has not changed in more than four decades.”
Noting that the phase